While Alzheimer’s disease (AD) has no cure, five prescription medicines have been approved by the U.S. Food and Drug Administration (FDA) to treat disease symptoms that impact thinking and memory.

Being started on a smaller dose of the approved early Alzheimer’s disease therapy Kisunla (donanemab) — by shifting one vial from the first to the third infusion treatment — reduces the risk of ARIA-E ...

Patients with Alzheimer’s disease (AD) experience a slow progressive decline in memory and cognitive ability, among other symptoms, due to the spread of damage in the brain. Generally, the disease is ...

There is a rapid growth in the number of people living with Alzheimer’s disease, and only around one in four people with the disease get diagnosed. It is estimated that there are approximately 44 ...

Both of my parents, Ruth and Jim Page Sr., have passed from this life to the next. They were tremendous people who loved each other and their children profoundly. They had many gifts, separately and ...

Alzheimer’s disease is a progressive neurodegenerative disorder characterized by declining mental abilities that affect a person’s memory, cognition, and personality. It is the most common cause of ...

Alzheimer’s disease is a progressive neurodegenerative disorder and the most common cause of dementia. It most often emerges during a person’s mid-60s or older, although early-onset varieties exist.

There is no cure for Alzheimer’s Disease (AD), but some medications may help reduce the symptoms or slow progression of the disease. As AD progresses, brain cells die and the connections between them ...

In Alzheimer’s disease (AD), significant numbers of nerve cells in the brain die, affecting patients’ ability to remember things and to think clearly — resulting in confusion, behavioral changes and ...

Alzheimer’s disease is an irreversible, progressive neurological disorder associated with a gradual decline in mental and physical abilities. It is considered the most common form of dementia. The ...

Namzaric (donepezil and memantine), also known as MDX-8704, ADS-8704, and Arimenda, is an approved therapy for moderate to severe Alzheimer’s disease. Allergan markets the treatment in the U.S. and ...